Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3068
Name glioblastoma
Definition A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes.
Source DiseaseOntology.org
Alt Ids DOID:3075 DOID:3080
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Tepotinib glioblastoma not applicable detail...
PTEN wild-type 2-Methoxyestradiol glioblastoma sensitive detail...
PTEN loss CCT128930 glioblastoma sensitive detail...
Unknown unknown Regorafenib glioblastoma not applicable detail...
TP53 mutant Adavosertib + Radiotherapy glioblastoma sensitive detail...
Unknown unknown Sunitinib glioblastoma no benefit detail...
MSH6 T1219I Temozolomide glioblastoma resistant detail...
Unknown unknown Enzastaurin glioblastoma not applicable detail...
Unknown unknown Bevacizumab glioblastoma not applicable detail...
Unknown unknown Ponatinib glioblastoma not applicable detail...
PTEN loss PF-04691502 glioblastoma sensitive detail...
FGFR3 - TACC3 U0126 glioblastoma sensitive detail...
FGFR3 over exp U0126 glioblastoma sensitive detail...
Unknown unknown LYS6KAKT1 glioblastoma not applicable detail...
Unknown unknown CC-115 glioblastoma not applicable detail...
Unknown unknown BMS-906024 glioblastoma not applicable detail...
IDH1 R132H Temozolomide + Vandetanib glioblastoma sensitive detail...
Unknown unknown Temozolomide + Vandetanib glioblastoma not applicable detail...
PTEN negative Temozolomide + Vandetanib glioblastoma no benefit detail...
Unknown unknown Tanibirumab glioblastoma not applicable detail...
Unknown unknown GSK1838705A glioblastoma not applicable detail...
FGFR3 - TACC3 Erdafitinib glioblastoma predicted - sensitive detail...
Unknown unknown MPS1-IN-3 + Vincristine Sulfate glioblastoma not applicable detail...
IDH1 mutant Bevacizumab + Lomustine glioblastoma predicted - sensitive detail...
Unknown unknown PRN1371 glioblastoma not applicable detail...
Unknown unknown COG112 glioblastoma not applicable detail...
Unknown unknown LB-100 glioblastoma not applicable detail...
Unknown unknown Imetelstat glioblastoma not applicable detail...
PIK3CA H1047Y YM-024 glioblastoma sensitive detail...
PIK3CA over exp YM-024 glioblastoma sensitive detail...
PIK3CA V344G YM-024 glioblastoma no benefit detail...
Unknown unknown Bortezomib + Vorinostat glioblastoma not applicable detail...
Unknown unknown Marizomib + Vorinostat glioblastoma not applicable detail...
Unknown unknown Bortezomib + Panobinostat glioblastoma not applicable detail...
Unknown unknown Marizomib + Panobinostat glioblastoma not applicable detail...
Unknown unknown SEN-450 + Temozolomide glioblastoma not applicable detail...
PTEN loss PKI-402 glioblastoma sensitive detail...
IDH1 mutant N/A glioblastoma not applicable detail...
ATRX loss Doxorubicin glioblastoma sensitive detail...
ATRX loss Irinotecan glioblastoma sensitive detail...
ATRX loss Topotecan glioblastoma sensitive detail...
PTEN V54fs XL147 glioblastoma sensitive detail...
Unknown unknown Valproic acid glioblastoma no benefit detail...
Unknown unknown Ad-RTS-IL-12 plus AL glioblastoma not applicable detail...
Unknown unknown Selinexor glioblastoma not applicable detail...
TP53 mutant Adavosertib glioblastoma sensitive detail...
Unknown unknown Abemaciclib glioblastoma not applicable detail...
PTEN loss A66 glioblastoma resistant detail...
Unknown unknown Dovitinib glioblastoma not applicable detail...
Unknown unknown Cediranib + Lomustine glioblastoma not applicable detail...
Unknown unknown Cediranib + Gefitinib glioblastoma not applicable detail...
Unknown unknown ST-11 glioblastoma not applicable detail...
Unknown unknown PF-00562271 glioblastoma not applicable detail...
Unknown unknown BLZ945 glioblastoma not applicable detail...
Unknown unknown BLZ945 + Buparlisib glioblastoma not applicable detail...
Unknown unknown Buparlisib glioblastoma no benefit detail...
PTEN loss BLZ945 glioblastoma no benefit detail...
TP53 loss BLZ945 glioblastoma sensitive detail...
Unknown unknown Radiotherapy + Temsirolimus glioblastoma no benefit detail...
PTEN loss LY3023414 glioblastoma sensitive detail...
Unknown unknown MGCD516 glioblastoma not applicable detail...
RB1 positive Palbociclib glioblastoma predicted - sensitive detail...
RB1 inact mut Palbociclib glioblastoma resistant detail...
Unknown unknown Durvalumab glioblastoma not applicable detail...
CDKN2A pos RB1 inact mut Palbociclib glioblastoma resistant detail...
CDKN2A del Palbociclib glioblastoma sensitive detail...
Unknown unknown SL-701 glioblastoma not applicable detail...
Unknown unknown Bevacizumab + SL-701 glioblastoma not applicable detail...
Unknown unknown Pexidartinib glioblastoma not applicable detail...
PTEN mut TP53 mut Navitoclax + ONC201 glioblastoma sensitive detail...
BRAF V600E PD-0325901 glioblastoma decreased response detail...
BRAF V600E PLX4720 glioblastoma decreased response detail...
Unknown unknown BI2536 glioblastoma not applicable detail...
BRAF V600E BI2536 glioblastoma sensitive detail...
Unknown unknown BI2536 + PD-0325901 glioblastoma not applicable detail...
BRAF V600E BI2536 + PLX4720 glioblastoma sensitive detail...
Unknown unknown GDC-0152 glioblastoma not applicable detail...
Unknown unknown PRX177561 + Sunitinib glioblastoma not applicable detail...
Unknown unknown Bevacizumab + PRX177561 glioblastoma not applicable detail...
PTEN loss GDC-0084 glioblastoma sensitive detail...
PTEN inact mut Voxtalisib glioblastoma sensitive detail...
PTEN inact mut SF1126 glioblastoma sensitive detail...
IDH2 R140Q Enasidenib glioblastoma predicted - sensitive detail...
IDH2 R172K Enasidenib glioblastoma predicted - sensitive detail...
Unknown unknown Alisertib glioblastoma not applicable detail...
Unknown unknown SA16 glioblastoma not applicable detail...
Unknown unknown MP7 glioblastoma no benefit detail...
Unknown unknown Alisertib + MP7 glioblastoma not applicable detail...
Unknown unknown G-TPP + Navitoclax glioblastoma not applicable detail...
Unknown unknown G-TPP + Obatoclax glioblastoma not applicable detail...
Unknown unknown G-TPP + WEHI-539 glioblastoma not applicable detail...
Unknown unknown G-TPP + Venetoclax glioblastoma not applicable detail...
Unknown unknown A-1210477 + G-TPP glioblastoma not applicable detail...
BRAF V600E Ulixertinib glioblastoma sensitive detail...
Unknown unknown A-966492 + Radiotherapy + Topotecan glioblastoma not applicable detail...
Unknown unknown SR9009 glioblastoma not applicable detail...
Unknown unknown BGB-5777 glioblastoma not applicable detail...
IDH2 mutant N/A glioblastoma not applicable detail...
Unknown unknown CID613034 glioblastoma not applicable detail...
Unknown unknown JR-AB2-011 glioblastoma not applicable detail...
Unknown unknown Everolimus + Vorolanib glioblastoma not applicable detail...
BRAF V600E Dabrafenib + Trametinib glioblastoma predicted - sensitive detail...
ATM positive AZD1390 glioblastoma sensitive detail...
TP53 mutant AZD1390 glioblastoma sensitive detail...
Unknown unknown VAL-083 glioblastoma not applicable detail...
Unknown unknown Adavosertib glioblastoma not applicable detail...
Unknown unknown DCVax-L glioblastoma not applicable detail...
Unknown unknown Gliovac + Sargramostim glioblastoma not applicable detail...
Unknown unknown WT2725 glioblastoma not applicable detail...
Unknown unknown PVSRIPO glioblastoma not applicable detail...
Unknown unknown Iniparib + Radiotherapy + Temozolomide glioblastoma not applicable detail...
IDH1 wild-type PTEN mut Pembrolizumab glioblastoma resistant detail...
IDH1 wild-type PTEN mut Nivolumab glioblastoma resistant detail...
BRAF mut IDH1 wild-type Pembrolizumab glioblastoma predicted - sensitive detail...
BRAF mut IDH1 wild-type Nivolumab glioblastoma predicted - sensitive detail...
Unknown unknown Relatlimab + Urelumab glioblastoma not applicable detail...
BRAF V600E Vemurafenib glioblastoma predicted - sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib glioblastoma predicted - sensitive detail...
Unknown unknown AOH1160 glioblastoma not applicable detail...
Unknown unknown AsiDNA glioblastoma not applicable detail...
Unknown unknown AsiDNA + Olaparib glioblastoma not applicable detail...
CDKN2A del RB1 pos Ribociclib glioblastoma predicted - sensitive detail...
Unknown unknown Plerixafor glioblastoma not applicable detail...
Unknown unknown Trabedersen glioblastoma not applicable detail...
IDH1 R132H Trichostatin A glioblastoma resistant detail...
IDH1 R132H Vorinostat glioblastoma resistant detail...
IDH1 R132H Valproic acid glioblastoma resistant detail...
IDH1 R132H AGI-5198 + Trichostatin A glioblastoma predicted - sensitive detail...
IDH1 R132H AGI-5198 + Vorinostat glioblastoma predicted - sensitive detail...
Unknown unknown Temozolomide + Vistusertib glioblastoma not applicable detail...
PTEN del Buparlisib + Capmatinib glioblastoma no benefit detail...
PTEN mutant Buparlisib + Capmatinib glioblastoma no benefit detail...
PTEN negative Buparlisib + Capmatinib glioblastoma no benefit detail...
Unknown unknown CYNK-001 glioblastoma not applicable detail...
Unknown unknown ICT-107 glioblastoma not applicable detail...
Unknown unknown Olaparib + Temozolomide glioblastoma not applicable detail...
Unknown unknown Olaparib + Radiotherapy glioblastoma not applicable detail...
Unknown unknown Perifosine glioblastoma no benefit detail...
Unknown unknown Bevacizumab + Trebananib glioblastoma no benefit detail...
Unknown unknown ONC201 glioblastoma not applicable detail...
IDH1 R132H DS-1001b glioblastoma sensitive detail...
PTEN loss GDC-0152 glioblastoma predicted - sensitive detail...
PTEN loss Birinapant glioblastoma predicted - sensitive detail...
PTEN loss UMI-77 glioblastoma sensitive detail...
PTEN loss A-1210477 glioblastoma sensitive detail...
PTEN loss S63845 glioblastoma sensitive detail...
PTEN loss AZD5991 glioblastoma sensitive detail...
PTEN loss Temozolomide + UMI-77 glioblastoma sensitive detail...
PTEN loss AZD5991 + Temozolomide glioblastoma sensitive detail...
Unknown unknown HSV-1 G207 glioblastoma not applicable detail...
BRAF V600E PLX8394 glioblastoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00054496 Phase II Erlotinib Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status USA 0
NCT00301418 Phase Ib/II Erlotinib Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma Completed USA 0
NCT00492687 Phase II Carboplatin Temozolomide Tamoxifen Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status USA 0
NCT00669669 Phase Ib/II O6-benzylguanine Carmustine + Filgrastim + Plerixafor + Temozolomide Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas Active, not recruiting USA 0
NCT00906516 Phase II 81C6 + Bevacizumab Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Unknown status USA 0
NCT00968240 Phase I Bevacizumab Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) Completed USA 0
NCT00998010 Phase II Bortezomib + Temozolomide Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed USA 0
NCT01052363 Phase I Bevacizumab + Fosbretabulin OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Withdrawn USA 0
NCT01067469 Phase II Bevacizumab Bevacizumab + Lomustine Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) Completed USA 0
NCT01107522 Phase I Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Unknown status USA 0
NCT01112527 Phase II Dacomitinib PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma Completed USA 0
NCT01130077 Phase I Poly ICLC A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas Recruiting USA 0
NCT01140568 Phase II Nilotinib Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas Completed USA 0
NCT01149850 Phase II Bevacizumab + Temozolomide Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma Active, not recruiting USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA 3
NCT01238237 Phase I Cetuximab Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma Completed USA 0
NCT01260506 Phase Ib/II Bevacizumab + VB-111 Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Completed USA 1
NCT01266031 Phase Ib/II Bevacizumab + Vorinostat Bevacizumab Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed USA 0
NCT01269424 Phase I O6-benzylguanine + Temozolomide O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma Active, not recruiting USA 0
NCT01269853 Phase Ib/II Bevacizumab Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA Recruiting USA 0
NCT01290263 Phase Ib/II Bevacizumab + Trebananib Trebananib Amgen 386 for Recurrent Glioblastoma Completed USA 0
NCT01331291 Phase II Bosutinib Bosutinib in Adult Patients With Recurrent Glioblastoma Completed USA 0
NCT01331616 Phase I Bevacizumab Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab Unknown status USA 0
NCT01339039 Phase I Bevacizumab + Plerixafor Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Terminated USA 0
NCT01349660 Phase Ib/II Bevacizumab + Buparlisib Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme Completed USA 0
NCT01386710 Phase Ib/II Bevacizumab + Carboplatin Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Suspended USA 0
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting USA 4
NCT01430351 Phase I Metformin + Temozolomide Mefloquine + Temozolomide Memantine + Metformin + Temozolomide Mefloquine + Memantine + Temozolomide Mefloquine + Memantine + Metformin + Temozolomide Temozolomide Mefloquine + Metformin + Temozolomide Memantine + Temozolomide Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy Active, not recruiting USA 0
NCT01434602 Phase Ib/II Everolimus + Sorafenib Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas Active, not recruiting USA 0
NCT01435395 Phase I Bevacizumab + Bortezomib + Temozolomide Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme Completed USA 0
NCT01473901 Phase I Buparlisib + Temozolomide A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed USA | CAN 2
NCT01478178 Phase Ib/II VAL-083 Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor Completed USA 0
NCT01478321 Phase II Bevacizumab + Temozolomide Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Terminated USA 0
NCT01508117 Phase II Axitinib Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients Terminated USA 0
NCT01526837 Phase I Bevacizumab Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence Terminated USA 0
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed USA | CAN 6
NCT01591577 Phase II Lapatinib + Temozolomide Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme Active, not recruiting USA 0
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | CAN 1
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed USA 0
NCT01672463 Phase I OKN-007 Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients Active, not recruiting USA 0
NCT01721577 Phase Ib/II AXL1717 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status USA 0
NCT01730950 Phase II Bevacizumab Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Active, not recruiting USA 0
NCT01753713 Phase II Dovitinib Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed USA 0
NCT01756352 Phase II Bevacizumab FET-PET for Evaluation of Response of Recurrent GBM to Avastin Completed USA 0
NCT01788280 Phase I Bevacizumab Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab Withdrawn USA 0
NCT01790503 Phase Ib/II Pexidartinib Temozolomide A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed USA 0
NCT01800695 Phase I Temozolomide Depatuxizumab mafodotin Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme Completed 0
NCT01811498 Phase Ib/II Bevacizumab Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM Active, not recruiting USA 0
NCT01814813 Phase II Bevacizumab Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Active, not recruiting USA 0
NCT01837862 Phase Ib/II Carboplatin + Mebendazole + Temozolomide + Vincristine Sulfate Bevacizumab + Irinotecan + Mebendazole A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting USA 0
NCT01849146 Phase I Adavosertib + Temozolomide WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme Active, not recruiting USA 0
NCT01860638 Phase III Bevacizumab Lomustine A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma Completed CAN 14
NCT01870726 Phase Ib/II Buparlisib + Capmatinib Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma Terminated USA 4
NCT01884740 Phase Ib/II Bevacizumab + Cetuximab Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age Recruiting USA 0
NCT01891747 Phase I Bevacizumab + Temozolomide A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma Active, not recruiting USA 0
NCT01894061 Phase II Bevacizumab NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Completed USA 0
NCT01903330 Phase II Bevacizumab Cyclophosphamide Sargramostim ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme Recruiting USA 0
NCT01904123 Phase I WP1066 A Phase I Trial of WP1066 Recruiting USA 0
NCT01925573 Phase I Bevacizumab NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) Terminated USA 0
NCT01931098 Phase II Pazopanib + Topotecan Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM) Completed USA 0
NCT01933815 Phase Ib/II Bevacizumab TPI 287 Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Suspended USA 0
NCT01934361 Phase Ib/II Buparlisib + Lomustine Buparlisib + Carboplatin Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Completed USA | CAN 4
NCT01954576 Phase II NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Recruiting USA 0
NCT01975701 Phase II Infigratinib A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Completed USA 5
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed USA 0
NCT01986348 Phase II Selinexor Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide Completed USA 2
NCT01989052 Phase Ib/II Lomustine Carboxyamidotriazole Orotate Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Terminated USA 0
NCT01999270 Phase I Bevacizumab + Irinotecan Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors Completed USA 0
NCT02010606 Phase I Bevacizumab Temozolomide Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma Active, not recruiting USA 0
NCT02017717 Phase III Nivolumab Bevacizumab Ipilimumab + Nivolumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting USA 11
NCT02026271 Phase I Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Active, not recruiting USA 0
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn USA 0
NCT02047214 Phase II Bevacizumab + Paclitaxel Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Terminated USA 0
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Active, not recruiting USA 9
NCT02067156 Phase II Mipsagargin Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma Completed USA 0
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Active, not recruiting USA 0
NCT02120287 Phase II Bevacizumab Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme Completed USA 0
NCT02133183 Phase I Sapanisertib TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma Active, not recruiting USA 0
NCT02137759 Phase II Vorinostat Temozolomide MRSI to Predict Response to RT/TMZ and Vorinostat in GBM Active, not recruiting USA 0
NCT02146066 Expanded access DCVax-L Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 Available USA 0
NCT02152982 Phase II Veliparib Temozolomide Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Active, not recruiting USA 1
NCT02157103 Phase II Bevacizumab A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma Completed USA 0
NCT02179086 Phase II Temozolomide Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting USA | CAN 0
NCT02197169 Phase I DNX-2401 DNX-2401 + Interferon gamma DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) Completed USA 0
NCT02238496 Phase II Perifosine + Temsirolimus Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Active, not recruiting USA 0
NCT02285959 Phase I Bevacizumab Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme Recruiting USA 0
NCT02287428 Phase I NeoVax Pembrolizumab Temozolomide NeoVax + Pembrolizumab + Temozolomide NeoVax + Pembrolizumab Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM Recruiting USA 0
NCT02311582 Phase Ib/II Pembrolizumab MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Recruiting USA 0
NCT02311920 Phase I Temozolomide Nivolumab Ipilimumab Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Active, not recruiting USA 0
NCT02315534 Phase Ib/II Napabucasin Temozolomide A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma Completed USA | CAN 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA 1
NCT02336165 Phase II Durvalumab Bevacizumab + Durvalumab Phase 2 Study of MEDI4736 in Patients With Glioblastoma Active, not recruiting USA 1
NCT02337491 Phase II Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab +/- Bevacizumab for Recurrent GBM Completed USA 0
NCT02340156 Phase II SGT-53 Temozolomide Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma Terminated USA 1
NCT02342379 Phase II Bevacizumab + Evofosfamide TH-302 in Combination With Bevacizumab for Glioblastoma Completed USA 0
NCT02343406 Phase II Lomustine Depatuxizumab mafodotin Temozolomide ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Completed USA | CAN 19
NCT02343549 Phase II Bevacizumab + Temozolomide LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer Terminated USA 0
NCT02345824 Phase I Ribociclib Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma Unknown status USA 0
NCT02348255 Phase II Bevacizumab + Carmustine NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse Withdrawn USA 0
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA 1
NCT02386826 Phase I Bevacizumab + Capmatinib INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Active, not recruiting USA 0
NCT02414165 Phase II Bevacizumab Lomustine Toca 511 + Toca FC Temozolomide P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) Terminated USA | CAN 2
NCT02423525 Phase I Afatinib Safety Study of Afatinib for Brain Cancer Active, not recruiting USA 0
NCT02465268 Phase II pp65 Dendritic Cell Vaccine + Sargramostim Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II) Recruiting USA 0
NCT02478164 Phase II Ponatinib Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma Completed USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02510950 Phase I Sargramostim Poly ICLC Temozolomide Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Terminated USA 0
NCT02511405 Phase III Bevacizumab VB-111 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Completed USA | CAN 1
NCT02521090 Phase Ib/II EGFRBi-armed autologous activated T cells EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma Withdrawn 0
NCT02525692 Phase II ONC201 Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma Recruiting USA 0
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02530502 Phase Ib/II Temozolomide Pembrolizumab Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Terminated USA 0
NCT02573324 Phase II Temozolomide Depatuxizumab mafodotin + Temozolomide A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) Active, not recruiting USA | CAN 26
NCT02586857 Phase Ib/II Acalabrutinib A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) Active, not recruiting USA 0
NCT02605746 Phase I Ceritinib Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis Completed USA 0
NCT02607124 Phase Ib/II Ribociclib Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Terminated USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA 1
NCT02617589 Phase III Nivolumab Temozolomide Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498) Active, not recruiting USA | CAN 17
NCT02619864 Phase Ib/II Vistusertib mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme Completed CAN 0
NCT02626364 Phase II Crenolanib Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification Completed USA 0
NCT02648633 Phase I Nivolumab + Valproic acid Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma Terminated USA 0
NCT02658981 Phase I Relatlimab Urelumab Nivolumab + Urelumab Nivolumab + Relatlimab Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) Active, not recruiting USA 0
NCT02661282 Phase Ib/II Autologous CMV-specific CTLs + Temozolomide Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Active, not recruiting USA 0
NCT02663271 Phase II Bevacizumab TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma Recruiting USA 0
NCT02667587 Phase II Temozolomide Nivolumab + Temozolomide Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer). Active, not recruiting USA | CAN 17
NCT02717962 Phase II VAL-083 Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma Recruiting USA 0
NCT02743078 Phase II Bevacizumab Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Terminated USA 0
NCT02754362 Phase II Poly ICLC Bevacizumab A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma Withdrawn USA 0
NCT02765165 Phase Ib/II Lomustine + USL311 USL311 Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) Terminated USA 1
NCT02766699 Phase I EGFR(V)-EDV-Dox A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV) Recruiting USA 0
NCT02768389 Phase I Bevacizumab Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Completed USA 0
NCT02780024 Phase II Metformin Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM Recruiting CAN 0
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Recruiting USA | CAN 2
NCT02798406 Phase II DNX-2401 + Pembrolizumab Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE) Active, not recruiting USA | CAN 0
NCT02800486 Phase II Cetuximab Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting USA 0
NCT02829723 Phase Ib/II BLZ945 BLZ945 + Spartalizumab Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Recruiting USA 7
NCT02844439 Phase II Tesevatinib Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma Completed USA 0
NCT02852655 Phase 0 Pembrolizumab A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Recruiting USA 0
NCT02858895 Phase II MDNA55 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed USA 0
NCT02861898 Phase Ib/II Cetuximab + Mannitol Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Recruiting USA 0
NCT02866747 Phase Ib/II Durvalumab A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI) Recruiting 1
NCT02871843 Phase I RRx-001 + Temozolomide Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) Active, not recruiting USA 0
NCT02876003 Phase II Mipsagargin Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Withdrawn USA 0
NCT02885324 Phase II Cabozantinib Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children Recruiting USA 0
NCT02928575 Phase II Sunitinib + Temozolomide Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma Unknown status CAN 0
NCT02942264 Phase Ib/II Zotiraciclib Temozolomide + Zotiraciclib TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Completed USA 0
NCT02968940 Phase II Avelumab Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Completed USA 0
NCT02974621 Phase II Bevacizumab Cediranib + Olaparib Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Active, not recruiting USA 0
NCT02977780 Phase II CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) Recruiting USA 0
NCT02981940 Phase II Abemaciclib A Study of Abemaciclib in Recurrent Glioblastoma Active, not recruiting USA 0
NCT03014804 Phase II DCVax-L DCVax-L + Nivolumab Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma Withdrawn USA 0
NCT03018288 Phase II Pembrolizumab + Temozolomide Pembrolizumab + Temozolomide + Vitespen Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Recruiting USA 0
NCT03027388 Phase I LB-100 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Recruiting USA 0
NCT03047473 Phase II Avelumab Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ) Active, not recruiting CAN 0
NCT03107780 Phase I KRT-232 Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Recruiting USA 0
NCT03128047 Phase I Bevacizumab + Temozolomide HUMC 1612: Optune NovoTTF-200A System Recruiting USA 0
NCT03139916 Phase II Bavituximab + Temozolomide Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Active, not recruiting USA 0
NCT03149003 Phase II Bevacizumab + DSP-7888 Bevacizumab A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G) Active, not recruiting USA | CAN 3
NCT03150862 Phase Ib/II Pamiparib Pamiparib + Temozolomide A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma Completed USA 3
NCT03174197 Phase Ib/II Atezolizumab + Temozolomide Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) Active, not recruiting USA 0
NCT03197506 Phase II Pembrolizumab + Temozolomide Pembrolizumab Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Recruiting USA 0
NCT03212742 Phase Ib/II Olaparib + Temozolomide Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients (OLA-TMZ-RTE-01) Recruiting 1
NCT03216499 Phase II PT2385 HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma Completed USA 0
NCT03223103 Phase I Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma Recruiting USA 0
NCT03224104 Phase I Radiotherapy + Zotiraciclib Zotiraciclib Temozolomide Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) Recruiting 5
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Completed USA 2
NCT03250299 Phase I BAL101553 Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Recruiting USA 0
NCT03277638 Phase Ib/II Pembrolizumab Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma Recruiting USA 0
NCT03294486 Phase Ib/II Flucytosine + TG6002 Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients (ONCOVIRAC) Recruiting 1
NCT03296696 Phase I AMG 596 Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma Active, not recruiting USA 5
NCT03332355 Phase I PAC-1 + Temozolomide Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 Suspended USA 0
NCT03341806 Phase I Avelumab Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma Recruiting USA 0
NCT03344250 Phase I EGFRBi-armed autologous activated T cells Phase I EGFR BATs in Newly Diagnosed Glioblastoma Recruiting USA 0
NCT03347617 Phase II Pembrolizumab Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma Recruiting USA 0
NCT03367715 Phase II Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Recruiting USA 0
NCT03382977 Phase I VBI-1901 Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects Active, not recruiting USA 0
NCT03405792 Phase II Pembrolizumab + Temozolomide Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) Recruiting USA 0
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Suspended USA 0
NCT03422094 Phase I Ipilimumab + NeoVax + Nivolumab NeoVax + Nivolumab Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Terminated USA 0
NCT03423628 Phase I AZD1390 A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Recruiting USA 1
NCT03425292 Phase I Temozolomide Ipilimumab + Nivolumab Nivolumab A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer Recruiting USA 0
NCT03426891 Phase I Pembrolizumab + Temozolomide + Vorinostat Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Recruiting USA 0
NCT03430791 Phase II Ipilimumab + Nivolumab Nivolumab Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma Terminated USA 0
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) Recruiting USA | CAN 1
NCT03452579 Phase II Bevacizumab + Nivolumab Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM Active, not recruiting USA 0
NCT03452930 Phase I Tinostamustine Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Recruiting USA 0
NCT03463265 Phase II Lomustine + Nab-Rapamycin Nab-Rapamycin Nab-Rapamycin + Temozolomide Bevacizumab + Nab-Rapamycin ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma Recruiting USA 0
NCT03491683 Phase Ib/II Cemiplimab + INO-5401 + INO-9012 + Temozolomide INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) Active, not recruiting USA 0
NCT03493932 Phase I Nivolumab + Relatlimab Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Active, not recruiting USA 0
NCT03514069 Phase I Ruxolitinib Ruxolitinib + Temozolomide Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma Recruiting USA 0
NCT03532295 Phase II Bevacizumab + Epacadostat + Radiotherapy + Retifanlimab Bevacizumab + Radiotherapy + Retifanlimab INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas Recruiting USA 0
NCT03535350 Phase I Ibrutinib Ibrutinib + Temozolomide Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Recruiting USA 0
NCT03581292 Phase II Temozolomide + Veliparib Veliparib Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations Recruiting USA | CAN 3
NCT03587038 Phase I OKN-007 + Temozolomide OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Recruiting USA 0
NCT03596086 Phase Ib/II HSV-Tk + Valacyclovir HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM Recruiting USA 0
NCT03603405 Phase Ib/II HSV-Tk HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM Recruiting USA 0
NCT03605550 Phase I PTC596 A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Recruiting USA 0
NCT03607643 Phase Ib/II Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Unknown status USA 0
NCT03636477 Phase I Ad-RTS-IL-12 plus AL + Nivolumab A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 Active, not recruiting USA 0
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Active, not recruiting USA | CAN 8
NCT03657576 Phase I C134-HSV-1 Trial of C134 in Patients With Recurrent GBM (C134-HSV-1) Active, not recruiting USA 0
NCT03661723 Phase II Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Recruiting USA 0
NCT03681028 Phase I Feasibility of Individualized Therapy for Recurrent GBM Active, not recruiting USA 0
NCT03688178 Phase II pp65 Dendritic Cell Vaccine + Temozolomide pp65 Dendritic Cell Vaccine + Temozolomide + Varlilumab DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe) Recruiting USA 0
NCT03696355 Phase I GDC-0084 Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas Active, not recruiting USA 0
NCT03707457 Phase I Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Terminated USA 0
NCT03726515 Phase I CART-EGFRvIII + Pembrolizumab CART-EGFRvIII + Pembrolizumab in GBM Completed USA 0
NCT03732352 Phase II Osimertinib 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma Active, not recruiting USA 0
NCT03743662 Phase II Nivolumab Bevacizumab Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma Recruiting USA 0
NCT03749187 Phase I Pamiparib + Temozolomide BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) Recruiting USA | CAN 0
NCT03776071 Phase III Enzastaurin Temozolomide Enzastaurin + Temozolomide A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 Recruiting USA 0
NCT03782415 Phase Ib/II Temozolomide Ibudilast + Temozolomide Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM Recruiting USA 0
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting USA | CAN 13
NCT03856099 Phase II Tanibirumab TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab Recruiting USA 1
NCT03893487 Phase I CUDC-907 Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) Recruiting USA 1
NCT03896568 Phase I DNX-2401 Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Recruiting USA 0
NCT03911388 Phase I HSV-1 G207 HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Recruiting USA 0
NCT03919071 Phase II Dabrafenib + Trametinib Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma Recruiting USA 1
NCT03961971 Phase I Sabatolimab + Spartalizumab Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM Recruiting USA 0
NCT03965494 Phase I Bemcentinib AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery Recruiting USA 0
NCT03970447 Phase II Lomustine Regorafenib Temozolomide A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) Recruiting USA | CAN 0
NCT03975829 FDA approved Dabrafenib + Trametinib Pediatric Long-Term Follow-up and Rollover Study Recruiting USA | CAN 3
NCT03995706 Phase I Sacituzumab govitecan-hziy Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 Recruiting USA 0
NCT04003649 Phase I Anti-IL13RA2 CAR T cells + Ipilimumab + Nivolumab Anti-IL13RA2 CAR T cells + Nivolumab IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma Recruiting USA 0
NCT04013672 Phase II Montanide ISA 51 + Pembrolizumab + Sargramostim + SurVaxM Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence Active, not recruiting USA 0
NCT04015700 Phase I GNOS-PV01 + INO-9012 Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma Recruiting USA 0
NCT04047303 Phase I CC-90010 CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma Active, not recruiting USA 1
NCT04049669 Phase II Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Recruiting USA 0
NCT04051606 Phase II Regorafenib Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma Recruiting USA 0
NCT04074785 Phase I Abemaciclib + Bevacizumab Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6 Recruiting USA 0
NCT04089449 Phase I PRT811 A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis Recruiting USA 0
NCT04116658 Phase Ib/II EO2401 First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (ROSALIE) Recruiting USA 3
NCT04118036 Phase II Abemaciclib + Pembrolizumab Abemaciclib + Pembrolizumab In Glioblastoma Suspended USA 0
NCT04145115 Phase II Ipilimumab + Nivolumab A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden Recruiting USA 1
NCT04195139 Phase II Nivolumab + Temozolomide Temozolomide Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG) Recruiting USA 1
NCT04197934 Phase I WSD0922 WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases Recruiting USA 0
NCT04201873 Phase I DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Pembrolizumab + Poly ICLC Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Recruiting USA 0
NCT04214392 Phase I Chlorotoxin-CD28-CD3z-CD19t CART cells Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of Recurrent or Progressive Glioblastoma Recruiting USA 0
NCT04216329 Phase I Selinexor + Temozolomide Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Recruiting USA 0
NCT04221503 Phase II Niraparib Niraparib/TTFields in GBM Recruiting USA 0
NCT04225039 Phase II INCAGN01876 + Retifanlimab Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma Recruiting USA 0
NCT04254419 Phase I Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas Not yet recruiting USA 0
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting USA 2
NCT04295759 Phase I INCB7839 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas Active, not recruiting USA 0
NCT04373785 Phase Ib/II NG101m + Temozolomide NG101m Adjuvant Therapy in Glioblastoma Patients Not yet recruiting USA 0
NCT04388475 Phase II OKN-007 + Temozolomide Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma Recruiting USA 0
NCT04396860 Phase II Temozolomide Ipilimumab + Nivolumab Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Recruiting USA 0
NCT04406272 Phase II Bevacizumab + VB-111 VB-111 in Surgically Accessible Recurrent/Progressive GBM Recruiting USA 0
NCT04421378 Phase Ib/II Lomustine + Selinexor Lomustine Selinexor + Temozolomide Temozolomide Selinexor A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Recruiting USA | CAN 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04444427 Phase Ib/II GLR2007 Evaluation of GLR2007 for Advanced Solid Tumors Recruiting USA 0
NCT04478279 Phase Ib/II ST-101 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04479241 Phase I Pembrolizumab + PVSRIPO A Phase 1 Study of PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma Recruiting USA 0
NCT04482933 Phase II HSV-1 G207 HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Not yet recruiting USA 0
NCT04555577 Phase I MSC2490484A Temozolomide Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma Recruiting USA 0
NCT04590664 Phase Ib/II Verteporfin Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma Recruiting USA 0
NCT04599647 Expanded access PVSRIPO EAP for the Treatment of Glioblastoma With PVSRIPO Available USA 0
NCT04606316 Phase I Nivolumab Ipilimumab + Nivolumab Surgical Nivolumab And Ipilimumab For Recurrent GBM Recruiting USA 0
NCT04608812 Phase I OS2966 Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection Recruiting USA 0
NCT04614909 Phase I Olaparib Pamiparib Pamiparib + Temozolomide Olaparib + Pamiparib + Temozolomide Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM Recruiting USA 0
NCT04629209 Phase II ONC201 A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma Withdrawn USA 0
NCT04655404 Phase I Larotrectinib A Pilot Study of Larotectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion (CONNECT1903) Recruiting USA | CAN 4
NCT04656535 Phase I GLS-010 AB154 AB154 + GLS-010 AB154 Combined With AB122 for Recurrent Glioblastoma Recruiting USA 0
NCT04691960 Phase II Metformin A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging Recruiting USA 0
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Recruiting USA 7
NCT04752813 Phase II BPM 31510 + Temozolomide A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) Not yet recruiting USA 0
NCT04765098 Phase II Tamoxifen Lomustine Tamoxifen Versus Lomustine After First Recurrence in GBM Patients Not yet recruiting CAN 0
NCT04809805 Phase I BAY2666605 A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer Recruiting USA 0
NCT04826393 Phase I ASP8374 + Cemiplimab ASP8374 + Cemiplimab in Recurrent Glioma Not yet recruiting USA 0
NCT04854044 Phase I ONC201 ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma Not yet recruiting USA 0